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Were he alive today, would Louis Pasteur still champion culture methods he pioneered over 150 years ago for
identifying bacterial pathogens? Or, might he suggest that new molecular techniques may prove a better way
forward for quickly detecting the true microbial diversity of wounds? As modern clinicians faced with treating
complex patients with diabetic foot infections (DFI), should we still request venerated and familiar culture and
sensitivity methods, or is it time to ask for newer molecular tests, such as 16S rRNA gene sequencing? Or, are
molecular techniques as yet too experimental, non-specific and expensive for current clinical use? While molecular
techniques help us to identify more microorganisms from a DFI, can they tell us ‘who done it?’, that is, which are
the causative pathogens and which are merely colonizers? Furthermore, can molecular techniques provide clinically
relevant, rapid information on the virulence of wound isolates and their antibiotic sensitivities? We herein review
current knowledge on the microbiology of DFI, from standard culture methods to the current era of rapid and
comprehensive ‘crime scene investigation’ (CSI) techniques.
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“[H]ave confidence in those powerful and safe
methods, of which we do not yet know all the
secrets.” “I am on the verge of mysteries, and the
veil is getting thinner and thinner.”
-Louis Pasteur [1]
This review is designed to address how to define dia-
betic foot infections (DFI) and to discuss the current un-
derstanding of the best way to evaluate the microbiology
of these complex infections. We also summarize new
data on the DFI microbiota, including the methodolo-
gical metamorphosis of our understanding from Pasteur’s
time to the current (and near-future) era. Further, we
present information on newly available molecular mi-
crobiology methods and examine innovative techno-
logies that may be used in the near future for defining
pathogens in DFI.* Correspondence: balipsky@uw.edu
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Wound infection: definition, process and prognosis
Foot wounds are an increasingly common problem in peo-
ple with diabetes and now constitute the most frequent
diabetes-related cause of hospitalization [2]. People with
diabetes have about a 25% chance of developing a foot
ulcer in their lifetime [3], about half of which are clinically
infected at presentation [2,4]. DFIs cause substantial mor-
bidity and at least one in five results in a lower extremity
amputation [5]. Amputation is even more likely when DFI
and foot ischemia coexist. [4,6] In fact, DFIs are now the
predominant proximate trigger for lower extremity ampu-
tations worldwide [7].
The pathophysiology of foot infections in persons with
diabetes is quite complex, but their prevalence and se-
verity are largely a consequence of host-related distur-
bances (immunopathy, neuropathy and arteriopathy) and
secondarily, pathogen-related factors (virulence, antibiotic-
resistance and microbial load) [2,8]. Typically, an in-
sensate, deformed foot develops an ulcer when some
form of trauma disrupts the protective skin envelope.
The underlying subcutaneous tissues then quickly be-
come colonized with bacteria, which may lead to infec-
tion, often initially clinically unapparent [7]. Infection isl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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wound that promotes deleterious inflammation or tissue
destruction [9]. Infection usually begins as a local process,
manifested by the classic signs and symptoms of inflam-
mation (redness, warmth, pain, tenderness, induration)
[10]. If not controlled, infection typically spreads—mostly
often contiguously—to deeper tissues. A host systemic in-
flammatory response syndrome (for example, fever, chills,
hypotension, tachycardia, delirium, leukocytosis) may ac-
company this process [10]. In some patients, especially
those with peripheral neuropathy or vasculopathy, these
symptoms and signs may be diminished [11,12], leading
some to advocate defining infection by the presence of
‘secondary’ findings, such as foul odor, friable or disco-
lored granulation tissue and rim undermining [13].
Some wound specialists believe that the presence of a
high concentration of microorganisms (usually defined
as >105 colony forming units [CFU] per gram of host tis-
sue [14]) in the absence of clinical evidence of infection
represents ‘increased bioburden’ or ‘critical colonization.’
They assert this may indicate wound infection [15,16],
or at least a degree of colonization that impairs wound
healing [12], and may overwhelm host defenses without
triggering a generalized immunological reaction [8]. There
is, however, no agreed means to define critical coloniza-
tion, no routine laboratory availability for quantitative bac-
teriology and no convincing evidence of its association
with adverse clinical outcomes, for example, failure of
healing or development of overt infection.
One study did find that in neuropathic diabetic foot
ulcers (DFUs) there was a significant inverse relationship
between exudate CFU count and rate of wound healing
[17]. But, in a cross-sectional study of 64 patients with a
non-ischemic DFU, no single sign or symptom generally
recognized as suggestive of infection, or any combin-
ation of them, correlated well with the quantitative mi-
crobial load [16]. Unfortunately, this lack of correlation
does not clarify whether clinical or microbiological re-
sults are most useful in defining infection. It may be that
the presence of specific types, or combinations, of bac-
teria, or their acquisition of certain virulence factors,
leads to clinical infection [12]. A prospective study of 77
patients with a neuropathic DFU and no clinical signs of
infection found that none of the three dimensions of
bioburden (that is, microbial load, microbial diversity
and presence of potential pathogens) correlated with DFU
outcomes. Some limitations of this study included the fact
that specimens were obtained from the ulcer by swab
(using ‘Levine’s technique’) and bioburden analysis was
done by culture-based methods [18].
Diabetic foot infection: bacteriology
Because many different organisms, alone or in combi-
nation, can cause a DFI, selecting the most appropriateantibiotic therapy requires defining the specific causative
pathogens [8,10,12]. Clinicians should avoid antibiotic
therapy that is unnecessary, overly broad-spectrum or
excessively prolonged, as it may cause drug-related ad-
verse effects, incurs financial cost and encourages anti-
microbial resistance [10].
Aerobic, Gram-positive cocci are the predominant or-
ganisms responsible for acute DFI, with Staphylococcus
aureus the most commonly isolated pathogen [10,19,20].
In wounds that are chronic, especially in patients who
have recently been treated with antimicrobial therapy,
infections are more frequently polymicrobial and the
causative pathogens are more diverse, often including
aerobic gram-negative bacilli and obligate anaerobic bac-
teria [10,21]. The presence of a mixture of bacterial types
appears to predispose to the production of virulence
factors, such as hemolysins, proteases and collagenases, as
well as short-chain fatty acids; these cause inflammation,
impede wound healing and contribute to the chronicity
of the infection [19,22]. In chronic, clinically uninfected
wounds, the presence of some microbes is potentially
advantageous, inducing passive resistance, metabolic co-
operation, quorum sensing systems and DNA sharing [23].
New data derived using molecular techniques demon-
strate that chronic wounds contain many different micro-
organisms some of which were not previously recognized
using standard culture methods. We are only in the early
stages of understanding the specific roles these micro-
organisms play in chronic wounds [23]. Moreover, recent
studies from less developed countries, especially in hot,
humid climates, report that even with standard micro-
biological methods aerobic gram-negative bacilli, espe-
cially Pseudomonas aeruginosa more often cause DFIs
[24]. While not yet adequately investigated, these findings
are probably related to various environmental, hygienic
and cultural issues. To better interpret culture results and
provide optimal antimicrobial therapy, clinicians must be
familiar with the microbial isolates in their own region of
practice. An additional pathogenic property of many or-
ganisms is their ability to become enveloped biofilm. This
has been best studied in S. aureus skin biofilms, which
appear to inhibit wound healing, diminish localized im-
munity and enable other microorganisms to colonize and
infect the wound [23]. Furthermore, consortia of geno-
typically distinct bacteria may symbiotically produce a
pathogenic community, referred to as functionally equiva-
lent pathogroups [25].
In the past few decades a major problem in treating
DFIs has been the increased rate of isolation of antibiotic-
resistant pathogens, particularly methicillin-resistant
S. aureus (MRSA), and to a lesser degree glycopeptide-
intermediate S. aureus (GISA), vancomycin-resistant en-
terococci (VRE), extended-spectrum β-lactamase- (ESBL)
or carbapenamase–producing gram-negative bacilli and
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tion of these multi-drug resistant pathogens vary widely
by geographical area and treatment center. But, the poten-
tial presence of such resistant isolates emphasizes the
importance of obtaining optimal specimens for culture
and sensitivity testing for infected DFIs [10,26], as well as
avoiding the excessive antibiotic therapy that drives this
resistance.
Evaluation of S. aureus virulence genes in DFU/DFI
Staphylococci, in addition to being the most frequent, are
perhaps the most virulent pathogens in DFI [10,19,20].
Studies in France have demonstrated a correlation be-
tween specific virulence genotypic markers in S. aureus
isolates from DFU and ulcer outcome [27-29]. Using a
miniaturized oligonucleotide array to identify genes en-
coding resistance determinants, toxins and species-
specific sequences of S. aureus, Sotto et al. sought to
differentiate colonized from infected wounds in diabetic
patients with a foot ulcer that was culture-positive for
only S. aureus. Virulence genes were absent in 20 of 22
(92%) clinically uninfected ulcers, but present in 49 of
50 (98%) infected ulcers [27]. In a follow-up study with
similar inclusion criteria, these investigators used poly-
merase chain reaction (PCR) assays to detect genetic
markers in both clinically uninfected and infected
diabetic foot ulcers. Analyzing for the presence of 31 of
the most prevalent virulence-associated S. aureus genes
they noted that a five-gene combination of capsular type 8
(cap8), Staphylococcus enterotoxin A (sea), Staphylococcus
enterotoxin I (sei), LukDE leukocidin (lukD/lukE) and ɤ-
hemolysin V (hlgv) was most predictive of clinical infec-
tion [28]. Then, using a new generation of miniaturized
oligonucleotide arrays for genotyping S. aureus that cov-
ered a larger number of genes, they compared the pres-
ence of each gene in S. aureus strains to the grades and
outcomes of diabetic foot ulcers. Using logistic analyses
they found that lukDE was the gene most predictive of a
favorable outcome of infection resolution or healing of
uninfected DFU [29]. These data demonstrate the poten-
tial of molecular methods for identifying virulence factors
in isolates from DFIs.
Defining DFI microbiota – a methodological
metamorphosis?
Over the past forty years studies to identify pathogens in
DFI have used standard microbiological methods, des-
pite their significant time to perform (two to three days
for preliminary results with final sensitivities often taking
longer), bias in species detected, lack of sensitivity (for
example, for fastidious organisms) and lack of informa-
tion on the relative prevalence of various pathogens and
their potential virulence. The recent availability of mo-
lecular techniques has shed new light on the microbialworld of diabetic foot wounds. They have generally
revealed the presence of many more organisms and
considerably more species (especially obligate anaerobes)
than found with standard cultures. However, molecular
methods also have some limitations, including high cost
and the need for substantial technician time for some
methods. Although advances in technology have produced
new desktop sequencers that are easy and somewhat
quicker to operate, these machines lack the sequencing
throughput required for microbial community sequen-
cing provided by larger-scale sequencers (for example,
Life Technology Ion Proton System or Illumina Hiseq
X Ten), which are generally available only in large-scale
centers. Moreover, the clinical significance of these micro-
biological findings is as yet unclear [30]. For example, al-
though we advocate selecting as focused an antimicrobial
regime as possible, we do not know if antibiotic treatment
must be directed at each isolated organism, or only at
presumed bacterial ‘ringleaders’, or even at organisms
that were once considered probable non-pathogenic ‘lab
weeds’ [31]. Thus, to better understand the microbial
diversity of wounds in DFI and to identify the relative pro-
portion and types of species in the wound some studies
have examined the results of using ‘crime scene investi-
gation (CSI)’-era technology (for example, small subunit
ribosomal RNA sequencing methods and real time PCR)
to standard culture methods [25,32-34].
Standard sample collection and bacterial culture
When obtaining a specimen for culture and sensitivity
testing, it is key to collect material that is not contamina-
ted with colonizing flora, but contains the true pathogens.
Since prior antibiotic therapy can cause false-negative cul-
tures, it is best if specimens can be obtained before such
therapy is begun. In some chronic infections, such as os-
teomyelitis, it is possible to safely discontinue antibiotic
therapy for at least a few days (or even weeks) before
obtaining deep cultures [35]. Specimens should be ob-
tained only after cleansing (with non-antimicrobial sub-
stances) and debriding the wound. While swabs of open
wounds are easy to obtain, most studies comparing them
to tissue specimens have shown that they are more apt to
grown contaminants and less likely to yield true pathogens
[21], especially when sampling bone [36]. Optimal speci-
mens for culture include tissue obtained by curettage of
debrided ulcer or a biopsy [37]. It is also important to
ensure the specimen is placed in an appropriate sterile
transport container, is rapidly sent to the microbiology
laboratory and once there is quickly processed.
Despite optimal specimen collection and processing,
culture-based techniques select for species that flourish
under typical nutritional and physiological conditions
of the microbiology laboratory but are potentially not
the most abundant or clinically important pathogens
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growing, fastidious or anaerobic organisms [34]. Per-
forming the 130-year-old method of the Gram-stained
smear of a wound specimen can provide rapid informa-
tion about the presence and type of microorganism and
their relative abundance in the tissue. Finally, we now
have newer, rapid tests that may provide a more accur-
ate snapshot of the wound microbiological milieu and
are widely used in clinical microbiology [7]. But, has
the promise of molecular microbiology been fulfilled
yet? Let us review concepts of molecular microbiology
as a step forward in identifying and better defining the
microbiome of DFI.
Molecular microbiology
PCR This is a molecular method to amplify a genomic
region of interest. When followed by DNA sequencing,
the abundance and genetic composition of a gene of
interest can be determined. The small subunit (SSU)
ribosomal RNA (rRNA) gene in bacteria, called 16S rRNA,
is a useful gene target given that it is conserved across all
prokaryotes (bacteria) but not eukaryotes (for example,
humans). In a clinical specimen, using universal primers
for bacteria in highly conserved regions of this gene per-
mits broad-range amplification by PCR of bacterial SSU
rRNA genes, but not human host genes. Simultaneously,
identifying species-specific hypervariable regions in the
16S rRNA gene allows for taxonomic classification of bac-
teria [38]. Following amplification by PCR, 16S rRNA gene
fragments are sequenced and analyzed using various me-
thods to assess the taxonomic composition and abundance
of bacterial communities [25,30,39,40]. Thus, the com-
bination of conserved primer-binding sites and inter-
vening variable sequences facilitates the identification
and quantification of microorganisms at the level of genus
and species, to permit a better understanding of a DFU
microbiome [30].
Currently, 16S rRNA quantitative PCR (qPCR) is used
to determine the biodiversity of wounds and estimate
bacterial load. Techniques for determining biodiversity
include full ribosomal amplification, cloning and Sanger
sequencing (FRACS), partial ribosomal amplification with
a gel band identification and Sanger sequencing (PRADS),
and density gradient gel electrophoresis (DGGE) [40].
Similarly, PCR assay or oligonucleotide array sequence
analyses (hybridization of a nucleic acid sample to a large
set of probes for gene mapping) can assess virulence-
associated genes [28,29,34,41]. Overall, PCR amplification
and sequencing allows for the quantification and analysis
of specific genes (or genomic regions) of interest.
Metagenomics In the past decade numerous molecular
methods have been introduced for detecting micro-
organisms from clinical specimens in a wound. Perhapsthe most revolutionary are those used to sequence DNA
directly from a sample, known as metagenomics [42].
Metagenomic methods can potentially provide not only
the names of the pathogens present in an infected wound,
but information on their virulence and their antibiotic
susceptibility patterns (to selected agents in some cases,
but to all drugs when needed), all within a time frame that
would allow replacing most empirical antibiotic selections
with evidence-based therapy [26,41]. This targeted diagno-
sis is fundamental for preventing the overuse of broad-
spectrum antibiotics that is one of the causes of the emer-
gence of bacterial resistance.
Metagenomic techniques allow for the complete cha-
racterization of all bacteria, archaea, fungi and viruses
within a sample (that is, the microbiome). Studies with
this method suggest that cultivable bacteria comprise
only a small fraction (<1%) of the total bacterial diversity
[43]. These culture independent methods are revolution-
izing clinical microbiology by providing a first glimpse
into microbial community structure and function rela-
tive to human health and disease [44-46]. The introduc-
tion of next-generation sequencing (NGS) technologies
(for example, 454/Roche pyrosequencing, Illumina and
Ion Torrent) [47-49] allows for the generation of DNA
sequence data more quickly and at decreased cost, which
should lead metagenomics from the ‘research’ realm into
the clinical microbiology laboratory. Metagenomic me-
thods differ from other molecular methods in the steps
involved to prepare samples for sequencing, time it takes
to obtain results, number of sequences generated and
bacterial diversity observable [23,40].
There are now two metagenomic methods for analy-
zing the microbes within a specimen, that is, community
profiling (using a single gene assay such as 16S rRNA)
and functional metagenomics (using total DNA), as shown
in Figure 1 and further described in Table 1 [50]. Metage-
nomic community profiles are produced by amplifying
regions in the SSU rRNA gene from genomic DNA in a
clinical sample and can be more accurate than culture-
based approaches [51,52]. Conversely, emerging functional
metagenomics methods provide a comprehensive look at
bacterial communities by sequencing all genomic DNA in
a sample rather than a single gene, such as the 16S rRNA
gene [53]. This allows for the characterization of bacteria
and their biological processes, including pathogenicity
islands (that is, the genetic element of an organism res-
ponsible for its capacity to cause disease), virulence factors,
and antibiotic resistance [54]. Furthermore, organisms can
be classified with better taxonomic resolution than single
gene assays, such as 16S rRNA [44,55].
Limitations of molecular microbiology
Despite their great possible clinical utility, each of these
molecular techniques (especially PCR based and functional



















































Figure 1 Overview of methods for community profiling and functional metagenomics. Patient tissue samples contain a mixture of human
and microbial DNA. Microbial DNA is derived from a community of bacteria and other organisms present at their relative abundance in the
sample, indicated here using different colors. Once DNA has been extracted from the sample, two metagenomic methods can be applied. In
functional metagenomics the total DNA is sequenced and analyzed by comparing it to databases of known genomes (for example, NCBI and
IMG) and 16S rRNA genes (for example, RDP, Green Genes and Silva) to identify bacterial taxa and their abundance. Sequences are also compared
to known proteins (for example, SIMAP, MG-RAST, KEGG) for functional analysis of genes, pathways and relative frequency. In community profiling,
hypervariable regions of the 16S rRNA gene from bacteria are amplified and sequenced. Highly similar sequences are binned by operational
taxonomic units and compared to databases of 16S rRNA genes from known bacteria (for example, RDP, Green Genes and Silva) to identify bacterial
taxa and their frequency. 16S rRNA gene sequences can be used in subsequent analyses of phylogenetic diversity in the sample. IMG: Integrated
Microbial Genomes; KEGG: Kyoto Encyclopedia of Genes and Genomes; MG-RAST: Metagenomic Rapid Annotations using Subsystems Technology;
NCBI: National Center for Biotechnology Information; OTU: Operational Taxonomic Unit; RDP: Ribosomal Database Project; SIMAP: Similarity Matrix
of Proteins.
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translation from research laboratory to clinical practice.
Overall, diagnostic tests based on PCR are subject to
issues related to detection sensitivity and specificity, which
may lead to an inaccurate portrayal of bacterial communi-
ties in wounds [56-58]. Specifically, PCR amplification of
genomic fragments requires that PCR primers are unique,
bind specifically to a region of interest and bind efficiently
enough to produce a PCR product. Given these criteria,
PCR primer design relies on a priori knowledge of
genomic sequences of bacteria in a wound (that may not
be cultivable and, therefore, amenable to genome sequen-
cing) and may not be broad enough to account for naturalvariation in bacteria in polymicrobial wound samples. As
a result, genomic fragments that are amplified by PCR
may be affected by primer bias, leading to inaccurate
representation of the bacterial community.
Even when PCR is successful, the targeted gene must
have enough discriminatory power to differentiate rela-
ted microorganisms. In particular, community profiling
based on single gene assays, such as 16S rRNA, may
yield inconclusive results for closely related species that
lack variation in this highly conserved gene. Moreover,
diagnostics based on a single gene, such as 16S rRNA,
are limited to bacterial community composition analysis,
thereby failing to capture clinically important functional
Table 1 Metagenomic methods: community profiling versus functional metagenomics
Common Features Unique to community profiling Unique to functional metagenomics
DNA obtained directly from a
wound sample; culture
independent
Marker genes such as 16S rRNA gene from a
community of bacteria, or 18S rRNA and internal
transcribed spacer (ITS) genes for fungi
Can provide genomic DNA from a community of
microorganisms. Applicable to all microorganisms
including bacteria, fungi, viruses and archaea
Need to remove human host DNA
contamination
PCR primers amplify only marker gene fragments
from targeted microbes, excluding DNA from the
human host
To avoid biases human DNA must be removed after
sequencing through computational methods
Sequenced using high-throughput
sequencing technologies
Sequencing errors in highly conserved marker genes
can lead to incorrect species assignment
Taxonomic assignment based on multiple genes from
genomic DNA can lead to more accurate taxonomic
community profiles
Reduction in the overall cost of
sequencing
Sequencing is directed at only microbial marker
genes, making sequencing more cost effective
Sequencing can be more cost-prohibitive due to
human host contamination (approximately 90% of
DNA in wound samples)
Data represent a community of
microorganisms and reflect
organismal diversity and abundance
Community profile is based only on taxonomy Community profile is based on taxonomy and function,
indicating the metabolic potential of a microbial
community
Less than 1% of organisms are
known, leading to incomplete
annotation
Closely-related organisms are indistinguishable based
on marker gene sequences alone. Not all bacteria are
represented in databases of known 16S rRNA genes
or 18S and internal transcribed spacer (ITS) for fungi
Not all microbial genomes exist in databases of known
species leading to difficulty in assigning sequences to
discrete organisms
Has potential for serendipitous
discovery of clinically relevant
organisms or function
Novel variations in the hypervariable regions of
marker genes can indicate new species
Genomes of unknown organisms can be reconstructed
from genomic fragments in metagenomes, providing
insights into new species and function
Has potential to find human-
microbe interactions
Can find links between microbial community
composition and clinical factors or patient outcomes
Can find links between microbial community
composition and function and clinical factors or patient
outcomes
Table 2 Key features of molecular methods for characterizing microorganisms from a diabetic foot infection





PCR and pyrosequencing Delineates full array bacteria present,
including almost all gram-positive,
gram-negative and obligate anaerobic
species; allows broad-range amplification
by PCR; detects even small concentrations
of microorganisms; avoids false-negative
results related to recent antibiotic therapy;
can help differentiate colonization from
infection
Identifies only 16S bacteria; fails to
detect some bacterial and nonbacterial
microorganisms; cannot reliably
distinguish between viable and
nonviable organisms as it amplifies
dormant or dead bacteria; unable to
test for phenotypic antibiotic sensitivity
4 to 24 hours About US $13/
target region
q PCR assaya Measures the quantity of a target
sequence; determines the number of
DNA copies in a sample; estimates
bacterial load; helps differentiate
colonization from infection
Quantifies DNA from both viable and
nonviable bacteria; requires a well-
equipped laboratory with PCR facilities
2 to 6 hours About US $10
per sample
Virulence genes factors for
S. aureusb
PCR assay Allows virulence genotyping among
strains of S. aureus
Only patients with monomicrobial
culture for S. aureus were included in
published study
2 to 5 hours About US $5/
assay
DNA microarray Carries a set of 334 different probes for
genotyping S. aureus isolates; analyzes a
large number of samples (96/well strip)
Only patients with monomicrobial
culture for S. aureus were included in
published study
4 to ~5 hours About US $ 60/
96-well strip
aIndicates that these molecular methods used 16S rRNA gene. In this table we decided to present one of methods (the newest) that have been used for
identification of bacterial diversity in the diabetic foot infection: PCR and pyrosequencing instead of other methods, such as PCR and Sanger sequencing.
bIndicates that these methods have been used for differentiating colonization from infection and non infected from infected ulcer in diabetic foot ulcer.
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resistance genes. Lastly, errors in sequencing, such as
well-documented issues with homopolymer regions in
454/Roche pyrosequencing [59], could lead to mis-
representation of bacterial communities.
In contrast to 16S rRNA community profiling, func-
tional metagenomics holds great promise in assessing
DFI, given that: sequencing is unbiased, allowing for ac-
curate measurement of species and bioburden in the
sample; it can be used for viruses that lack conserved
genes, such as 16S rRNA; it can be used to analyze mul-
tiple genes at one time, including virulence and anti-
biotic resistance factors; and, it can be used to discover
new pathogens or virulence factors. Major concerns with
this approach are that datasets are more costly to pro-
duce and larger and more complex to analyze. Moreover,
it is challenging to separate human-host DNA from
microbial DNA in skin samples and to obtain enriched
microbial genomic DNA for sequencing [60]. Of the
total DNA in a skin sample, approximately 90% is
human. Thus, defining microbial DNA requires deep
sequencing at a higher cost, with subsequent in silicoFigure 2 Proposed algorithm for diabetic foot or other chronic wound(computer) removal of human sequence contaminants,
making functional metagenomics not conducive to rapid
diagnosis. Because of this limitation all studies to date
on DFU and DFI have been based entirely on 16S rRNA
community profiling.
In Table 2 we have summarized the potential advan-
tages, selected disadvantages and costs of molecular
methods that are more apt to be taken up in the clinical
microbiology laboratory (metagenomic community pro-
filing, qPCR and virulence genes assays). Given limita-
tions associated with the various methods described, we
propose a three-pronged molecular approach: 1) identifi-
cation of bacterial diversity; 2) quantification of micro-
bial load; and 3) identification of virulence factors of any
S. aureus isolates. This methodology may allow for a
rapid and broader understanding of the microbiological
factors affecting a DFU (see Figure 2).
Finally, translating large-scale metagenomic datasets
into a clinical report requires the synthesis of bacterial
abundance, virulence factors and antibiotic resistance to-
wards understanding the full susceptibility profile of path-
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(rRNA) gene from genomic DNA. 
The 16S rRNA gene has species-
bacteria. 
C Sample Requirements:( 1) Fresh 
tissues are the preferred specimen, 
(2) The material should not be 
contaminated with exogenous 
bacteria, (3) Tissue samples should 
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Figure 3 Example of a potential microbiology report produced using the results of 16S rRNA (NGS) data. Example of a potential
microbiology report produced using the results of 16S rRNA NGS data from an actual patient specimen from the Southern Arizona Limb Salvage
Alliance clinic. A) Patient and specimen information, B) Test description and overview, C) Sample preparation requirements, D) List of any
resistance or virulence factors detected (note that this test does not yield these data), E) Bacterial taxonomic profile, F) Antibiotic susceptibility
profile based on the bacterial taxa detected in this sample. NGS, next-generation sequencing.
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tional metagenomics (Figure 4) to demonstrate the
increased resolution that clinicians might expect to see
when moving from Pasteur to CSI.
Microbial diversity and bacterial load in patients with DFU:
molecular versus culture techniques
Several recent studies have compared standard culture
to molecular community profiling techniques to assess the
effectiveness of each approach in characterizing bacterial
diversity and microbial load in DFU and DFI [34,40,61].
Although the types of wounds and methodology differed
in the studies, we will focus our discussion on the analysis
of diabetic foot ulcers.
Dowd et al. performed a comprehensive survey of bac-
terial diversity on three groups of patients with chronic
wounds with pathogenic biofilms, including one group
with DFU [40]. Analyses of a single pooled sample of the
10 patients in the DFU group for 16S partial ribosomal
amplification and 454/Roche pyrosequencing generated
approximately 36,000 sequences. Rhoads et al. compared
results of parallel samples processed by aerobic culture
versus 16S rRNA partial ribosomal amplification and 454/
Roche pyrosequencing from 168 patients with chronic
wounds, including 40 on the lower extremity of diabetic
patients [61]. Gardner et al. compared the results detected
by community profiling versus culture of three dimen-
sions of DFU bioburden (microbial diversity, microbial
load and pathogenicity) in 52 patients with DFUs. Micro-
bial diversity was defined as the number of bacterial taxa
present using 16S rRNA community profiling and micro-
bial load was defined as the total quantity of microbes
present using quantitative real time PCR. Sequences were
assigned to operational taxonomic units (OTU), mole-
cular proxies for describing organisms based on their
phylogenetic relationship to other organisms. Because
pathophysiologically distinct DFUs likely lead to con-
founding identification of microbial diversity, all 52
subjects selected had only a specific homogeneous type of
wound, that is, a neuropathic nonischemic DFU. Roche/
454 pyrosequencing showed an average of 5,634 sequen-
ces generated per sample [34].
These studies reported somewhat different taxonomic
compositions of DFUs. Dowd et al. found the primary bac-
terial genera were Staphylococcus (29.7%), Peptoniphilus
(6.9%), Rhodopseudomonas (6.9%) and Enterococcus (6.4%)
[40]. Facultative and strictly anaerobic gram-positive cocciwere the most prevalent isolates. They used two traditional
methods: FRACS showed the overwhelmingly predom-
inant species was S. aureus, followed by Anaerococcus
lactolyticus, Anaerococcus vaginalis, Bacterioides fragilis,
Finegoldia magna and Morganella morganii; PRADS
identified Pseudomonas, Haemophilus, Citrobacter and
Stenotrophomonas as the predominant species. The mo-
lecular methods differ in the number of sequences ge-
nerated and the variety of bacteria found with different
physiological and phenotypic preferences. Molecular me-
thods identified all bacterial isolates found on standard
culture, but they were performed during the study, while
the cultures were reviewed retrospectively [40].
In the Rhoads et al. study, the most common genera
detected in DFU by molecular testing were Corynebac-
terium, Peptoniphilus, Staphylococcus, Anaerococcus and
Bacteroides, while the most frequent on culture were
species of Enterococcus, Staphylococcus, Pseudomonas,
Serratia and Proteus [61]. Finally, Gardner et al. detected
a total of 13 phyla, with the majority of sequences being
Firmicutes (67%), Actinobacteria (14%), Proteobacteria
(9.8%), Bacteroidetes (7.3%) and Fusobacteria (1.4%). The
most abundant OTU, Staphylococcus, comprised 29% of
all sequences. Culture results showed a much higher rela-
tive abundance of Staphylococcus (46%) and a much lower
prevalence of anaerobic bacteria (12%). Furthermore, cul-
tures substantially underestimated the bacterial load based
on qPCR of the 16S rRNA gene by an average 2.34 logs
and, in some cases, by more than 6 logs [34].
Taken together, these three studies strongly suggest
that molecular techniques, such as 16S rRNA commu-
nity profiling, identify a greater diversity of organisms
than do standard microbiological methods. In particular,
they reveal more fastidious anaerobes and gram-negative
species than previously recognized. These results have
been affirmed in clinical case studies that have demons-
trated the potential utility of 16S rRNA community profil-
ing over culture [62].
Translating new technologies for bacterial identification
to the clinic - a possible future use in DFI?
New point-of-care (POC) testing methods may be useful
in a variety of clinical settings. The ideal diagnostic test
would be accurate, portable, low cost, and require min-
imal technical skills. POC testing could be used by the
patient (or care-giver or visiting nurse) at home in se-
lected circumstances, and could also help determine the
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Figure 4 Example of a potential microbiology report based on hypothetical functional metagenomic next generation sequencing
(NGS) data. Example of a potential microbiology report based on hypothetical functional metagenomic NGS data from a patient specimen.
A) Patient and specimen information, B) Test description and overview, C) Sample preparation requirements, D) List of any resistance or virulence
factors detected, E) Bacterial taxonomic profile, F) Antibiotic susceptibility profile based on bacterial taxa detected and antibiotic resistance and
virulence factors detected.
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needed by a patient. In evaluating a diabetic foot wound
in the outpatient setting, POC testing could provide a
mechanism for early detection of infection, allowing
clinicians to determine which wounds to culture and to
provide definitive (rather than empiric) antibiotic therapy
before the patient leaves the clinic [63]. We can (or soon
will be able to) get all of this clinically useful information
in ‘real’ time, before the clinician sits down to write orders
for further microbiological testing or antibiotic treatment.
The United States Food and Drug Administration (FDA)
has already approved rapid antigen tests for a variety of
selected pathogens. While viral assays currently have
the lion’s share of these approvals [63] it is likely they
will be increasingly used for bacterial identification,
including for diagnosing DFI pathogens. Advanced
microbiology diagnostic tests provide the promise of
dramatically increased sensitivity of pathogen identifica-
tion in decreased time.
Conclusions
We are at a critical juncture in the diagnosis of com-
municable diseases. With the advent of new molecular
technologies we can now detect and monitor many pa-
thogens much more rapidly and accurately than with the
clinical microbiology methods largely developed 150
years ago by Pasteur. While culture-based techniques
have served us well, overcoming their deficiencies will
afford us the ability to determine who needs antimicro-
bial therapy, as well as to quickly select the most appro-
priate treatment regimen. The currently available data
suggest that the promise of molecular microbiology
is on the verge of being fulfilled. But, like almost all
technological breakthroughs, from tanks to transistors,
we must learn how best to use them. Specifically, we
will need to carefully evaluate these new methods to
better understand if the extra data they provide is clin-
ically useful. If so, we will need to ensure their proper
translation into the clinical microbiology laboratory
and clinical settings. The ability to integrate data from
16S rRNA PCR, NGS, qPCR and virulence factor de-
tection from a sample collected from a diabetic foot
wound should lead to more accurate diagnosis and
targeted antibiotic therapy. We should soon be able to
put a swab/probe/new device into a cleaned wound and
get a report on which organisms are present, in what
amounts, with what virulence and antibiotic resistancegenes– all within an hour (or less). In this way, we will
indeed be transitioning from ‘Pasteur to CSI.’
“Gentlemen: It is the microbes who will have the
last word”
-Louis Pasteur [1]
“We solve these cases regardless of race, color,
creed, or bubblegum flavor!”
- Grissom, “CSI” [64]
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